Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation reports developments across its biopharmaceutical business in cardiometabolic and orphan lung diseases. Company updates center on commercial products such as Afrezza, an inhaled insulin for diabetes, and Furoscix, a furosemide injection for fluid overload in heart failure and chronic kidney disease, as well as financial results, product demand, launch infrastructure and capital-structure actions.
MannKind news also covers dry powder inhalation programs and drug-device combinations, including work using its Technosphere platform. Recurring topics include Afrezza clinical and real-world data, Furoscix device and regulatory updates, Nintedanib DPI for idiopathic pulmonary fibrosis, ralinepag DPI collaboration activity with United Therapeutics, and other pipeline decisions affecting inhaled therapies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MannKind Corporation (Nasdaq: MNKD) has appointed Lauren Sabella as Executive Vice President and Chief Operating Officer effective March 27, 2023. Reporting directly to CEO Michael Castagna, Sabella brings over 12 years of experience from Acorda Therapeutics, where she served as COO. Her previous roles include Chief Commercial Officer and Vice President of Commercial Development, contributing to significant product launches with peak sales exceeding $1 billion. Sabella will oversee critical operations in Danbury, focusing on expanding MannKind's endocrine business and preparing to launch new products in the orphan lung disease market.
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 2:00 PM (ET). Interested parties can access the live webcast through the company's website, with a replay available for 14 days after the event.
MannKind focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases, utilizing dry-powder formulations and inhalation devices for effective medicine delivery. The company is committed to addressing medical needs related to diabetes and pulmonary diseases.
MannKind Corporation (Nasdaq: MNKD) reported a total revenue of $100 million for 2022, reflecting a 32% increase from 2021. The fourth quarter revenues reached $36 million, a significant 188% rise year-over-year. Notable contributors include $12 million from Afrezza, with a gross margin of 92%, and $5 million from the newly acquired V-Go product. However, collaborations and services saw a 23% decline year-over-year, primarily due to the conclusion of a partnership with United Therapeutics. The company held $173 million in cash and equivalents at year-end, supporting ongoing R&D investments, including a Phase 3 trial for Afrezza in pediatrics.
MannKind Corporation (Nasdaq: MNKD) announced that its inhaled Technosphere Insulin (TI) demonstrated faster glucose control in a recent pilot study, lowering peak glucose levels 30 minutes faster than traditional rapid-acting insulin via an Automated Insulin Delivery (AID) system. The study involved 26 adults with type 1 diabetes, with TI achieving a lower post-prandial glucose from 45 to 120 minutes post-meal. MannKind plans a larger study to further explore TI's efficiency compared to traditional insulin methods, aiming to improve mealtime glucose control significantly.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., February 16, 2023 — MannKind Corporation (Nasdaq: MNKD) is set to release its 2022 fourth quarter and full year financial results on February 23, 2023, at 5:00 PM ET. The management will host a conference call to discuss these results and provide corporate updates. Presenters include CEO Michael Castagna and CFO Steven B. Binder. Interested parties can tune in via MannKind's website, with a replay available for 14 days. The company focuses on developing innovative therapeutic products for serious medical needs, particularly in endocrine and orphan lung diseases, utilizing dry-powder formulations and inhalation devices.